vs
合众银行（HBCP）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是合众银行的1.8倍（$69.8M vs $38.2M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 29.7%，领先354.3%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 7.4%）
该企业是总部位于美国明尼苏达州明尼阿波利斯、在特拉华州注册的跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的银行，主营银行、投资、抵押贷款等各类金融业务。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
HBCP vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.8倍
$38.2M
净利率更高
RIGL
高出354.3%
29.7%
两年增速更快
RIGL
近两年复合增速
7.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.2M | $69.8M |
| 净利润 | $11.4M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 29.7% | 384.0% |
| 营收同比 | — | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $1.45 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HBCPRIGL
| Q1 26 | $38.2M | — | ||
| Q4 25 | $38.0M | $69.8M | ||
| Q3 25 | $37.8M | $69.5M | ||
| Q2 25 | $37.1M | $101.7M | ||
| Q1 25 | $35.8M | $53.3M | ||
| Q4 24 | $35.2M | $57.6M | ||
| Q3 24 | $34.1M | $55.3M | ||
| Q2 24 | $33.1M | $36.8M |
净利润HBCPRIGL
| Q1 26 | $11.4M | — | ||
| Q4 25 | $11.4M | $268.1M | ||
| Q3 25 | $12.4M | $27.9M | ||
| Q2 25 | $11.3M | $59.6M | ||
| Q1 25 | $11.0M | $11.4M | ||
| Q4 24 | $9.7M | $14.3M | ||
| Q3 24 | $9.4M | $12.4M | ||
| Q2 24 | $8.1M | $-1.0M |
毛利率HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% |
营业利润率HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | 38.2% | 33.2% | ||
| Q3 25 | 41.1% | 40.9% | ||
| Q2 25 | 38.2% | 60.1% | ||
| Q1 25 | 38.6% | 23.9% | ||
| Q4 24 | 34.0% | 28.9% | ||
| Q3 24 | 34.3% | 25.4% | ||
| Q2 24 | 30.4% | 1.2% |
净利率HBCPRIGL
| Q1 26 | 29.7% | — | ||
| Q4 25 | 30.0% | 384.0% | ||
| Q3 25 | 32.7% | 40.2% | ||
| Q2 25 | 30.6% | 58.6% | ||
| Q1 25 | 30.7% | 21.5% | ||
| Q4 24 | 27.5% | 24.9% | ||
| Q3 24 | 27.7% | 22.5% | ||
| Q2 24 | 24.5% | -2.8% |
每股收益（稀释后）HBCPRIGL
| Q1 26 | $1.45 | — | ||
| Q4 25 | $1.46 | $14.11 | ||
| Q3 25 | $1.59 | $1.46 | ||
| Q2 25 | $1.45 | $3.28 | ||
| Q1 25 | $1.37 | $0.63 | ||
| Q4 24 | $1.21 | $0.82 | ||
| Q3 24 | $1.18 | $0.70 | ||
| Q2 24 | $1.02 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $223.5M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $444.4M | $391.5M |
| 总资产 | $3.6B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资HBCPRIGL
| Q1 26 | $223.5M | — | ||
| Q4 25 | — | $155.0M | ||
| Q3 25 | — | $137.1M | ||
| Q2 25 | — | $108.4M | ||
| Q1 25 | — | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $49.1M |
总债务HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M |
股东权益HBCPRIGL
| Q1 26 | $444.4M | — | ||
| Q4 25 | $435.1M | $391.5M | ||
| Q3 25 | $423.0M | $117.6M | ||
| Q2 25 | $408.8M | $81.9M | ||
| Q1 25 | $402.8M | $18.6M | ||
| Q4 24 | $396.1M | $3.3M | ||
| Q3 24 | $393.5M | $-14.6M | ||
| Q2 24 | $375.8M | $-29.9M |
总资产HBCPRIGL
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.5B | $513.6M | ||
| Q3 25 | $3.5B | $242.5M | ||
| Q2 25 | $3.5B | $206.7M | ||
| Q1 25 | $3.5B | $176.0M | ||
| Q4 24 | $3.4B | $164.0M | ||
| Q3 24 | $3.4B | $139.4M | ||
| Q2 24 | $3.4B | $128.4M |
负债/权益比HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | $54.5M | $22.0M | ||
| Q3 25 | $21.5M | $24.0M | ||
| Q2 25 | $8.7M | $30.5M | ||
| Q1 25 | $12.6M | $-893.0K | ||
| Q4 24 | $48.7M | $14.5M | ||
| Q3 24 | $17.6M | $21.7M | ||
| Q2 24 | $15.0M | $302.0K |
自由现金流HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | $44.3M | — | ||
| Q3 25 | $20.7M | — | ||
| Q2 25 | $7.9M | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $44.7M | — | ||
| Q3 24 | $17.0M | — | ||
| Q2 24 | $13.4M | — |
自由现金流率HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | — | ||
| Q3 25 | 54.6% | — | ||
| Q2 25 | 21.3% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 126.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 40.3% | — |
资本支出强度HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | 26.7% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 10.8% | — | ||
| Q4 24 | 11.5% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 4.9% | — |
现金转化率HBCPRIGL
| Q1 26 | — | — | ||
| Q4 25 | 4.78× | 0.08× | ||
| Q3 25 | 1.74× | 0.86× | ||
| Q2 25 | 0.77× | 0.51× | ||
| Q1 25 | 1.15× | -0.08× | ||
| Q4 24 | 5.04× | 1.01× | ||
| Q3 24 | 1.87× | 1.75× | ||
| Q2 24 | 1.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HBCP
| Net Interest Income | $34.5M | 90% |
| Noninterest Income | $3.7M | 10% |
RIGL
暂无分部数据
